11
Aug 26
29
Jul 26
24
Jun 26
24
Jun 26
12
May 26
03
Mar 26
28
Jan 26
CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
Completed private placement financing of up to approximately $49 million to advance pulmonary hypertension program Auxora Phase 1b proof-of-concept data in pulmonary arterial hypertension (PAH) and CM5480 IND submission both anticipated in mid-2027 FDA aligned that the primary endpoint for the
CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints
FDA aligned on new-onset severe respiratory failure as the Phase 2b primary endpoint, with multi-organ failure and time to medically indicated discharge as key secondary endpoints FDA aligned on a strategy to evaluate elevated lactate dehydrogenase (LDH) as a potential enrichment marker for
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program
Proceeds expected to support a focused pulmonary hypertension strategy, including a Phase 1b proof-of-concept study evaluating Auxora™ in PAH, with data anticipated mid-2027, and advancement of oral CRAC channel inhibitor CM5480 to IND clearance expected mid-2027 Anticipated cash runway into 2H
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
FDA reviewed a protocol amendment and interim safety data from the KOURAGE trial evaluating Auxora in AKI patients No comments or questions were received Confirms CalciMedica's ability to continue clinical development of Auxora across indications LA JOLLA, Calif., June 24, 2026 /PRNewswire/ --
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 Preclinical and IND-enabling studies advancing for CM5480, an oral CRAC channel inhibitor candidate, with IND submission in pulmonary hypertension expected
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates
Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™ D esign of pivotal program in acute pancreatitis (AP) expected in 1H 2026 JCI Insight publication of preclinical
CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation
Safety concern warrants reevaluation of study design, including enrollment criteria Potential future trial with Auxora ™ in AKI to be evaluated after data analysis LA JOLLA, Calif., Jan. 28, 2026 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica " or the "Company") (Nasdaq: CALC), a clinical-stage